SOURCE: Wall Street Press Wire

Wall Street Press Wire

April 02, 2008 09:43 ET

Stocks to Watch for Thursday: OCOL, PFE, BMY, MRK

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding.

MIAMI, FL--(Marketwire - April 2, 2008) - Wall Street Press Wire (www.WallStreetPressWire.com) is pleased to highlight its "stocks on the move" for Tuesday. Our list includes: Oncolin Therapeutics (OTCBB: OCOL), Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb Company (NYSE: BMY) and Merck & Co., Inc. (NYSE: MRK).

Having just received an intermediate term price target of $1.45, Wall Street Press Wire is initiating its in-depth coverage of Oncolin Therapeutics (OTCBB: OCOL), a biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies.

Tuesday after the markets closed, the company issued an important press release announcing that it has obtained an exclusive worldwide right to option patents covering the composition and use of Genistein analogs for cancer treatment.

This news should be welcomed by the company and its investors! The technology was discovered and patented by the Pharmaceutical Research Institute of Warsaw Poland and involves compounds that appear to be novel antimicrotubule agents. Given the widespread success of antimicrotubule therapies in curative and palliative cancer treatment, the microtubule is perhaps the single best cancer target identified to date and continues to be recognized as a strategic target against which to direct new development efforts.

The approved drugs from this mechanistic class include the Vinca alkaloids such as vincristine, the taxanes with paclitaxel and docetaxel and the epothilones with its first drug recently approved by Bristol Myers. Each of these different types of compound classes appear to interact at different parts of the microtubule and have different spectrums of activity and show effectiveness against resistant disease.

"We are happy to have obtained this exclusive agreement on what may be another unique antimicrotubule class of compounds. We will work closely with both the Pharmaceutical Research Institute of Warsaw Poland and the MD Anderson Cancer Center to further evaluate the compounds anticancer activity to continue to advance a lead compound into clinical development," said Dr. Donald Picker, President and COO of the company.

Other recent news that should be of interest of investors includes:

Oncolin Announces Its Research Program Receives Peer Reviewed National Institute of Health Grant of $179,000.

Oncolin has recently announced it has obtained an exclusive option agreement with The University of Texas M.D. Anderson Cancer Center which provides the Company the right to negotiate a license for five technologies relating to the treatment of various cancers over a nine month period.

Oncolin has recently announced a Joint Development Agreement with Houston Pharmaceuticals to assist the Company in obtaining a license for certain patents.

Wall Street Press Wire's in-depth profile for Oncolin Therapeutics is available at: http://www.wallstreetnewsalert.com/hotstocks/ocol040108/default.aspx

The stock closed Tuesday at Forty Five cents a share.

Pfizer Inc. (NYSE: PFE) up 2.1% on 37.4 million shares traded. Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health. The company discovers, develops, manufactures and delivers quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals.

Bristol-Myers Squibb Company (NYSE: BMY) up 4.1% on 16.3 million shares traded. Bristol-Myers Squibb Company is a global biopharmaceutical and related health care products company whose mission is to extend and enhance human life.

Merck & Co., Inc. (NYSE: MRK) up 0.9% on 41.3 million shares traded. Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs.

Wall Street Press Wire:

Wall Street Press Wire (WSPW) is the premiere online financial destination of choice for today's investment community, and a leading provider of online press release distribution and a disseminator of electronic information. From Wall Street to Main Street, our goal is to bridge the gap between emerging publicly traded companies and shareholders across the country.

With many small publicly traded companies operating under the radar of mainstream Wall Street, our service places their news story in front of the eyes of the investment community. Utilizing a targeted distribution approach, their story reaches the top news websites on the web and thousands of investors nationwide. For more information on our products, please visit: http://www.wallstreetpresswire.com/content.php?UID=5

Wall Street Press Wire (WSPW) is a division of Wall Street Capital Funding LLC (WSCF). WSCF also maintains a contractual, working relationship with Stock Market Alerts LLC and its' Wall Street Enews brand. WSPW is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. WSPW profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release. All statements and expressions are the sole opinion of WSPW and are subject to change without notice. Information in this release is derived from a variety of sources including that company's publicly disseminated information, third parties and WSPW research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. WSPW disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies' discussed in this release is highly speculative and carries a high degree of risk. WSPW is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSPW profiled stocks.

This profile is not without bias, and is a paid release. WSCF expects to be compensated Twenty Two Thousand Dollars for coverage of Oncolin Therapeutics (OTCBB: OCOL), previously known as Edgeline Holdings, Inc. (OTCBB: ELHI), by the company, for services provided including dissemination of company information in this release. Prior to the name and symbol change, WSCF was previously compensated for services rendered in 2008 and 2007; the previous compensation can be viewed by looking at a previous WSNA, ELHI press release. WSCF holds no shares of the stock. WSCF may receive compensation for future services. Any additional compensation will be disclosed at such time that WSCF is aware of a clients desire to begin services. WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF. WSCF's services for a company may cause the company's stock price to increase, in which event WSCF would make a profit when it sells its stock in a company. In addition, WSCF's selling of a company's stock may have a negative effect on the market price of the stock.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSPW undertakes no obligation to update such statements

Contact Information